Clinical Trials Browser

Phase 1/2 × Lymphoma, Mantle-Cell × ublituximab × Clear all

NCT04692155 2023-09-28

CHOP U2

Phase 1/2 Terminated

1 enrolled 5 charts

Lymphoma, Mantle-Cell

NCT02013128 2022-10-24

Ublituximab + Ibrutinib in Select B-cell Malignancies

Phase 1/2 Completed

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell